Clinical Trial

The Sahlgrenska Anti-VEGF Study

Study acronym: SAHLVE
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study investigates whether patients treated for neovascular (wet) age-related macular degeneration (AMD), with intravitreal injection with bevacizumab (Avastin) after two years need more injections with retained therapy response compared to patients being treated with intravitreal injection with aflibercept (Eylea). The study also aims to evaluate if there is a difference in best-corrected visual acuity, macular thickness, recurrence interval, durability, cost efficiency, as well as vision-related quality of life.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2019-09-22; most recent amendment 2025-11-17.
Status change: Recruiting → Active, Not Recruiting 2025-11-17
Status change: Not Yet Recruiting → Recruiting 2021-01-28
Trial Details
NCT Number NCT04101877
Lead Sponsor Vastra Gotaland Region
Conditions Neovascular Age-related Macular Degeneration
Enrollment 402 participants
Start Date 2020-09-03
Primary Completion 2026-10 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2025-11-21